SpencerKSullivanMD

Pediatric Anemia and Red Blood Cell Hematology, Pediatric Coagulation Disorder Hematology, Pediatric Platelet Disorder Hematology

CEO, Mississippi Center for Advanced Medicine

Dr. Sullivan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
7730 Old Canton Rd
Bldg B
Madison, MS 39110
Phone+1 601-499-0935

Fax+1 601-499-0936

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2009 - 2012
University of Virginia Medical CenterFellowship, Blood Banking/Transfusion Medicine, 2008 - 2009
University of Virginia Medical CenterResidency, Pediatrics, 2005 - 2008
University of North Carolina at Chapel Hill School of MedicineClass of 2005

PubMed

453 citations
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
Lindsey A. George, Spencer K. Sullivan, Adam Giermasz, John E.J. Rasko, Benjamin J. Samelson-Jones
The New England Journal of Medicine. 2017-12-06
90 citations
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.
Lindsey A. George, Paul E Monahan, M Elaine Eyster, Spencer K. Sullivan, Margaret V Ragni
The New England Journal of Medicine. 2021-11-18
89 citations
Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia
Shilpa Gandre-Babbe, Prasuna Paluru, Chiaka Aribeana, Stella T. Chou, Silvia Bresolin
Blood. 2011-11-18

Abstracts/Posters

Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year
Spencer K. Sullivan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Gene Therapy SPK-8016 Shows Early Promise for Severe Hemophilia AFebruary 8th, 2021
Spark Therapeutics Announces Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX ActivityJune 13th, 2016

MCAM Websitehttp://www.msadvancedmedicine.com
MCAM Facebookhttps://www.facebook.com/MississippiAdvancedMedicine/?ref=bookmarks